Amcinonide

Sold as Cyclocort. Every FDA application for this active ingredient: 3 branded and 5 generic.

As of Nov 14, 2026, FDA lists 8 applications for Amcinonide (sold as Cyclocort), first approved Oct 18, 1979, with 0 new uses approved and 0 published complete response letters.

First approved: Oct 18, 1979
Applications: 8
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $11.7M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Amcinonide	Part D	$11.7M	+162%	1,995

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

AMCINONIDE 0.1% CREAM: $4.90 per GMGeneric · -48% in a year

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Oct 18, 1979	CyclocortNDA 18116 · New molecular entity	Astellas	9	Discontinued
Nov 13, 1981	CyclocortNDA 18498 · New dosage form	Astellas	11	Discontinued
Jun 13, 1988	CyclocortNDA 19729 · New dosage form	Astellas	7	Discontinued
May 31, 2002	AmcinonideANDA 76229	Taro Pharm Inds	0	Marketed
Nov 6, 2002	AmcinonideANDA 76329	Solubiomix	0	Marketed
Nov 19, 2002	AmcinonideANDA 76096	Genus	0	Marketed
Mar 19, 2003	AmcinonideANDA 76367	Taro Pharm Inds	0	Discontinued
May 15, 2003	AmcinonideANDA 76065	Genus Lifesciences	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA